The company that built an entire gemstone category is being sold for the price of a modest suburban strip mall. Charles & Colvard, the North Carolina firm that commercialized lab-grown moissanite in 1995 and trades under the ticker CTHR, had its Chapter 11 asset sale approved by the US Bankruptcy Court for the Eastern District of North Carolina on June 25. The winning bidder, AJS Creations, will pay $2.7 million in cash, with closing required by July 7. For a business that once positioned itself as the branded alternative to mined stones, that is a sobering valuation.

A category creator undone by its own category

Charles & Colvard commercialized moissanite, a silicon carbide gemstone, under its Forever One brand, and later extended into lab-grown diamonds with its Caydia line. It went public in 1997 and, based in Research Triangle Park, spent nearly three decades as one of the few pure-play public companies in the lab-created gem business. For years it held a genuine technical and branding lead in a niche it had effectively invented.

The financial arc tells the story. The company booked $43.1 million in revenue at its 2020 pandemic peak, when consumers cooped up at home poured discretionary cash into jewelry and online engagement-ring sales surged. Last year it managed $16 million, a decline of roughly 63% from that high. Its bankruptcy petition listed $19.2 million in assets against $10.5 million in debts, and it operated a single brick-and-mortar store with about 60 employees.

The board chair attributed the collapse to increasing saturation in the market of companies producing lab-grown diamonds and gemstones, which continues to drive down the value of those gems. That is the same dynamic squeezing every retailer that stocked lab-grown as a growth category: prices that only fall, and margins that fall with them. A one-carat lab-grown round now retails near $725, and premium specifications have reached what analysts describe as a functional price floor. That backdrop, and the parallel reset in natural rough, is covered alongside the De Beers July sight in this week's diamond report.

The auction math

The sale process itself is instructive on where value has gone. An initial stalking-horse bid of $1.5 million came from Van Lang Jewelry and Jewelry Design Partners. At the June 22 auction, AJS Creations overbid to $2.7 million, an outcome that nearly doubled the floor price but still valued a 31-year-old public company's operating assets below $3 million. There are no planned layoffs tied to the transaction, and the buyer is acquiring specified business assets and assuming certain liabilities. A competitive auction that still tops out under $3 million says as much about the sector as it does about the company: buyers exist, but nobody is paying a premium for a lab-grown brand right now.

AJS Creations is a jewelry manufacturer rather than a strategic technology acquirer, which shapes what actually survives. The Forever One and Caydia brand names, the customer file, and the manufacturing know-how are worth something to an operator that can fold them into an existing production line and strip out overhead. What did not command a premium was the standalone public-company structure, the single retail store, and the direct-to-consumer marketing engine that once justified a far higher valuation. That is the tell. The market paid for the assets that lower a manufacturer's costs and passed on everything tied to selling lab-grown at retail as a business of its own.

What it signals for the trade

Charles & Colvard is not a Signet or a Pandora, and its failure will not reshape mall traffic on its own. But it is a clean data point in an argument the trade has been having for two years. When a category's wholesale value falls 80% to 90% below the natural product and keeps sliding, the producers and pure-play retailers who bet the business on it run out of room before the discounters and the diamond houses do. The independent jeweler who treated lab-grown as a traffic driver and a bridal-price opener, rather than a margin engine, is better positioned than the specialist who staked a public company on it.

The weekly context across gold, watches, and diamonds is in the trade wrap. For the lab-grown segment specifically, the question this filing raises is uncomfortable: if the pioneer that invented moissanite could not make the economics work at $16 million in revenue, how many of the newer online-only sellers are running the same losing math right now?